Defiance Daily Target 2X Long HIMS ETF

Hims & Hers Health Increases Convertible Note Offering to $350 Million

Hims & Hers Health Average Target Price Rises to $27.51

JPMorgan Downgrades Hims & Hers Health's Price Target to $33

Hims & Hers Health Misses Q1 Earnings Estimates, Shares Fall

Morgan Stanley Maintains Hold Rating on Hims & Hers Health with $21 Price Target

Hims &amp; Hers launches new membership program around weight loss drugs

Hims & Hers Reports FY2025 Revenue and FY2026 Forecast

Hims & Hers Promotes Cancer Blood Test Amid Concerns

Hims & Hers Health Inc. Collaborates with GRAIL to Offer Multi-Cancer Early Detection Test

Amesite

Meiwu Tech

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Generation Income Properties

MetaVia

NextNRG

Co-Diagnostics

Phoenix Asia

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

HIMS

HIMZ

Hims & Hers Health Inc. shares fell 8% following the announcement of a $300 million convertible notes offering, raising concerns about investor dilution. The company plans to use the proceeds for international growth, technology investments, and to support the acquisition of Eucalyptus. The notes will mature in 2032 and may be converted under specific conditions. HIMS stock has declined approximately 63% over the past year.

benzinga_article

Hims & Hers Health

Why Is Hims & Hers Stock Sinking Monday?

Hims has priced an upsized $350 million offering of 0.00% convertible senior notes due 2032, increased from $300 million. The funds will support international expansion and AI investments, with estimated net proceeds of approximately $338.5 million. The initial conversion rate is set at 33.8590 shares per $1,000 principal, reflecting a ~32.5% premium to the recent stock price.

TradingView

Hims prices $350M 0.00% convertible notes due 2032, upsized from $300M

Hims & Hers Health has upsized its private offering of 0% convertible senior notes to $350 million, increased from $300 million. The offering, due June 1, 2032, includes a 13-day option for initial purchasers to buy an additional $52.5 million. Proceeds will fund capped call transactions, support the acquisition of Eucalyptus, and cover general corporate purposes. The offering is expected to close Thursday.

Fidelity

iShares US Healthcare Providers

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

Hims & Hers Health Prices Upsized $350 Million Notes Offering

HIMY

Hims & Hers Health reported disappointing Q1 results, leading to a 14.07% drop in shares. Revenue was $608 million, missing estimates, while EBITDA fell to $44.3 million. Analysts had mixed reactions: JPMorgan maintained an Overweight rating but lowered the price target to $33; Needham kept a Buy rating and raised the target to $35; BTIG reaffirmed a Neutral rating. The company raised its 2026 revenue outlook despite lowering EBITDA guidance by $25 million, citing concerns over margin pressure from the shift to branded GLP-1s.

Defiance Leveraged Long +Income HIMS ETF

JPMorgan Chase

Novo Nordisk AS

OpenAI

Shutterstock

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Hims & Hers Health Posts Mixed Q1 Amid Weight-Loss Product 'Noise': Analysts

ASTS

ASTX

U.S. stock futures are down, with the Nasdaq falling 200 points. AST SpaceMobile shares dropped 11% after reporting a quarterly loss of 66 cents per share, missing estimates. Other stocks like Microvast Holdings, Zoominfo Technologies, and Hims & Hers Health also saw significant declines in pre-market trading due to disappointing financial results. Overall, several companies reported worse-than-expected earnings, contributing to the downward trend in the market.

AST SpaceMobile

Tradr 2X Long ASTS Daily ETF

GitLab

NASDAQ Composite Index

Microvast

ZoomInfo Tech

Power Solutions

Harrow

Bakkt

Webtoon ENT

CleanSpark

Life360

Microvast Holdings - CW26

Harrow Health Pref Share HROWM 11.875 12/31/27

Harrow Health Pref Share HROWL 8.625 04/30/26

BAKKT INC C/WTS 25/10/2026 (TO PUR COM)

CLEANSPARK INC C/WTS 29/12/2028 (TO PUR COM)

AST SpaceMobile Posts Downbeat Q1 Results, Joins Hims & Hers Health, Gitlab And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures fell on Tuesday due to a higher-than-expected April inflation reading of 3.8%. The Nasdaq 100, S&P 500, and Dow Jones futures dropped by 0.94%, 0.43%, and 0.08%, respectively. Oil prices rose amid ongoing U.S.-Iran tensions, with Brent crude up 3.46%. In pre-market trading, Under Armour, Hims & Hers Health, and AST SpaceMobile stocks saw significant declines, while Wendy's stock surged over 16% following news of potential privatization efforts by Trian Fund Management.

Tip Ranks

Under Armour-C

Wendys

NASDAQ-100

S&P 500

Dow Jones Industrial Average

Invesco QQQ Trust

Under Armour

U.S. Stock Futures Fall on April Inflation Reading, Persistent Geopolitical Tensions

ARMK

EATZ

Top Wall Street analysts have updated their ratings on several companies. Baird raised Aramark's price target from $50 to $58, maintaining an Outperform rating, while Aramark shares closed at $48.41. Other notable changes include BMO Capital increasing Nextpower's target from $113 to $125, and Mizuho cutting Agree Realty's target from $86 to $80. Analysts also adjusted targets for companies like Arvinas, Intellia Therapeutics, and Hims & Hers Health. For a complete list of changes, see the analyst ratings page.

Aramark

AdvisorShares Restaurant ETF

Nextpower

Agree Realty

Arvinas

Intellia Therap

Sensata Tech

Aecom

Arteris

AGREE REALTY CORP DEP SHS EA REP 1/1000 CUM PFD STK SR A

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Hims & Hers Health reported Q1 earnings impacted by margin pressure but anticipates increased revenue for Q2. The company is experiencing stability that could lead to a market squeeze. Recent FDA rulings on GLP-1 compounding may benefit Hims, and a rating upgrade is noted. Additionally, insights on shorted healthcare stocks are provided.

Earnings snapshot: Hims & Hers Health Q1 earnings hit by margin pressure; lifts Q2 revenue

Hims & Hers Health (HIMS) saw its stock drop 10% in after-hours trading after reporting Q1 revenue of $608 million, missing the $616.8 million estimate. The company also posted a loss per share of -$0.40, while analysts expected a profit of $0.03. Despite lowering its revenue guidance to $2.8-$3 billion, Wall Street had anticipated $2.7 billion. The company is under scrutiny following a legal issue with Novo Nordisk over a weight-loss pill. HIMS has a consensus Moderate Buy rating among analysts, with an average price target of $28.02, indicating a potential 4% downside.

HIMS Earnings: Hims & Hers Stock Falls 10% as Financial Results Miss Wall Street Targets

Hims & Hers Health, Inc. stock's average price target has increased from $27.17 to $27.51, indicating a potential downside of approximately 6% based on the May 11 closing price. The consensus rating remains a "Buy" among 20 analysts, with 7 Buys, 13 Holds, and no Sells. Forecasts for the stock range from $18 to $35 per share.

Factset Research

Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $27.51, Implies 6% Downside

Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)